Breast Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Patients must fit into one of three groups (cohorts) described below.
- Cohort 1: People who previously took part in the TAILORx study, received a recurrence score (a lab test result) anywhere between 0 and 100, and have since had a biopsy confirming that their cancer came back — either in the same area, in a distant part of the body, or both.
- Cohort 2: People who previously took part in Step 2 of the RxPONDER study, received a recurrence score between 0 and 25, and have since had a biopsy confirming that their cancer came back — either in the same area, in a distant part of the body, or both.
- Cohort 3: People who previously took part in Step 1 of the RxPONDER study and were found to have a high Oncotype DX recurrence score between 26 and 100.
- People who are able to understand and willing to sign a written consent form to take part in this observational (non-treatment) study; people who cannot make this decision independently but have a legally authorised representative, caregiver, or family member available may also be considered eligible.
- People in Cohorts 1 and 2 must have a tumour tissue sample from when their cancer came back, available at the time of joining, to be sent to the study's central facility within 30 days of registration.
- People in Cohort 3 must have a tumour tissue sample from their original (primary) tumour available at the time of joining, to be sent to the study's central facility within 30 days of registration.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- No exclusion criteria were listed in the source information (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Joseph A Sparano, MD, Eastern Cooperative Oncology Group
Phone: 212-659-6754
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Patterns of clonal evolution; Prevalence of the integrative cluster (IntClust) and intrinsic (PAM50) subtypes; Molecular signatures of primary tumor specimens
Can't join this trial?
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.